Lyrolin

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lyrolin

Property Description
Active Ingredients Pregabalin, Nortriptyline
Form Oral Tablet
Pharmacological Class Neuropathic Pain Agent, Combination
General Purpose Modulating chronic nerve discomfort
Origin Synthetic

Lyrolin is defined as a specialized prescription drug provided for oral use, formulated as a combination medicine in a tablet dosage form. It is primarily classified as a Neuropathic Pain Agent due to its targeted action on discomfort that originates from damaged or malfunctioning nerves. The fundamental characteristic of Lyrolin lies in its status as a combination product, which strategically incorporates two established medications. This dual strategy is clinically recognized for providing enhanced therapeutic benefits over monotherapy for managing complex neuropathic pain.

The pharmacological composition of Lyrolin is based on two distinct active ingredients: Pregabalin and Nortriptyline. Pregabalin is formally classified as an anticonvulsant that functions as an alpha2delta ligand, while Nortriptyline is a member of the tricyclic antidepressant class. This specific dual component approach is mirrored in several similar combination formulations, such as Nortryptomer-P and Pregalift NT, demonstrating the industry's recognized efficacy of this combined mechanism. This combination product status means the medicine addresses nerve hypersensitivity through two separate, established pathways.

The general purpose of Lyrolin is to provide integrated relief for persistent nerve discomfort by modulating the transmission of pain signals within the Central Nervous System (CNS). It achieves this through a coordinated approach that simultaneously works to stabilize overactive nerve signals and enhances the body's natural pain control pathways. Both Pregabalin and Nortriptyline are used in managing neuropathic pain states. This sophisticated, dual-action strategy allows Lyrolin to address the deep-seated hypersensitivity and dysfunction common in chronic neuropathic pain states.

Regulatory References

  1. Pregabalin: MedlinePlus Drug Information

What side effects are possible with Lyrolin?

Adverse Reactions and Safety Warnings

Lyrolin is associated with a range of side effects, primarily affecting the central nervous system. The most very common adverse reactions reported (occurring in more than 1 in 10 patients per EMA data) are dizziness and somnolence (sleepiness). Other common reactions include headache, peripheral edema (swelling of the extremities), weight gain, dry mouth, and blurred vision.

Serious and Clinically Significant Risks

Regulatory agencies have issued warnings regarding several serious adverse reactions:

  • Angioedema and Hypersensitivity Reactions: Swelling of the face, lips, tongue, or throat can occur, potentially leading to life-threatening respiratory compromise that requires emergency intervention.
  • Suicidal Behavior and Ideation: Like other antiepileptic drugs, Lyrolin carries an increased risk of suicidal thoughts or behavior; patients must be monitored for new or worsening depression or unusual changes in mood or behavior.
  • Respiratory Depression: Serious breathing difficulties, including slow or shallow breathing, have been reported, especially when Lyrolin is used with CNS depressants (such as opioids) or in patients with underlying respiratory impairment or advanced age.
  • Abrupt Discontinuation: Stopping the medication rapidly can increase the risk of seizures in patients with seizure disorders and may cause withdrawal symptoms, including insomnia, nausea, headache, and anxiety. The drug must be tapered gradually over at least one week.

Population and Dose Considerations

Dose adjustments are necessary for patients with renal impairment as Lyrolin is primarily excreted by the kidneys. Elderly patients are at a higher risk for falls due to dizziness and somnolence. The drug is classified as a Schedule V controlled substance by the U.S. FDA due to its potential for misuse and dependence. Adverse event profiles, including dizziness and somnolence, are generally considered dose-dependent.

Safety Restrictions

Lyrolin is contraindicated in patients with known hypersensitivity to the drug. Caution is advised when co-administering with thiazolidinedione antidiabetic agents due to increased risk of peripheral edema, and with any CNS depressants due to the risk of respiratory depression.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Lyrolin is defined by severe manifestations associated with its two active components, as documented in regulatory sources. Symptoms reported include central nervous system (CNS) effects such as extreme somnolence, confusion, disorientation, agitation, and loss of coordination (ataxia).

Severe and Life-Threatening Outcomes

The official prescribing information emphasizes the potential for severe outcomes, which necessitate immediate medical intervention. These include life-threatening Cardiovascular Toxicity, such as cardiac arrhythmias and severe hypotension, primarily linked to the Nortriptyline component. The overdose profile also documents Respiratory Depression (slowed or difficult breathing), Seizures, and Coma.

When to Seek Immediate Medical Attention

Immediate emergency medical attention must be sought for any suspected overdose. Urgent medical help is specifically required if a patient exhibits signs of life-threatening respiratory problems, such as bluish-colored skin (cyanosis) or unresponsiveness. Due to the rapid onset risk of severe cardiotoxicity, close hospital monitoring is mandatory.

Official Management Statements

Official management is described as supportive care. Regulatory documents note that no specific antidote is known for the Pregabalin component. For population-specific concerns, the risk of respiratory depression is increased in the elderly, and the risk of suicidal thinking is noted in young adults (ages 18 to 24) using the antidepressant component.

Therapeutic Uses of Lyrolin

What Lyrolin Treats: Main Uses and Benefits

Lyrolin is commonly used for the management of chronic neuropathic pain, which is discomfort resulting from damage to the sensory nervous system. This therapeutic domain is relevant in conditions characterized by periods of heightened symptoms, such as persistent discomfort from Diabetic Peripheral Neuropathy, Fibromyalgia, and Post-Herpetic Neuralgia (pain following shingles). The medication is applied across domains where additional symptomatic support is needed, especially where functional stability becomes affected due to nerve irritation.

The medication helps address specific, pronounced symptom patterns, including sensations often described as burning, shooting, stabbing, or intense tingling in the affected areas. It is relevant when symptoms also involve extreme hyper-sensitivity to non-painful stimuli. Providing supportive relief against these distressing manifestations contributes to easing the overall symptom load.

By supporting the moderation of heightened neurological activity, Lyrolin contributes to overall patient benefit by easing the symptom burden that interferes with sleep quality and routine daily function. It is often applied in scenarios where chronic pain has caused pain-induced sleep disruption, offering symptomatic relief that assists with maintaining functional stability during long-term nerve management.


Quick Fact: Relief for Chronic Neuropathic Pain The medication is relevant in situations where symptoms interfere with daily comfort, supporting the management of long-term nerve irritation that impacts sleep and comfort.

Eligibility and Restrictions for Use

Who Can and Cannot Use Lyrolin?

Lyrolin is defined by official regulatory bodies through specific eligibility and non-eligibility rules that govern its population use.

Absolute Prohibitions (Contraindications) The medicine is strictly contraindicated for several populations. You must not use Lyrolin if you have:

  • Known hypersensitivity (allergy) to Pregabalin, Nortriptyline, or any excipient.
  • Recent or current use of a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.
  • Severe cardiac conditions, including the acute recovery phase following a myocardial infarction or specific cardiac conduction defects (e.g., Heart Block).
  • Severe Liver Disease.

Eligibility by Age and Physiological State

Age Group Regulatory Status
Children and Adolescents (˂18) Not recommended; use is not established.
Adults (≥18) Eligible under standard conditions.
Elderly Patients (≥65) Special caution required; potential dose reduction needed.

Use is also not recommended during pregnancy or breastfeeding due to potential risks, as stated in official labeling.

Condition-Based Restrictions Patients with reduced kidney function (renal impairment) require a mandatory dose reduction adjusted according to their measured renal function. Use is also restricted or requires caution in individuals with a history of seizure disorders or conditions like narrow-angle glaucoma or urinary retention.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Lyrolin's interaction profile is derived from its two active components, Pregabalin and Nortriptyline, and includes documented pharmacokinetic and pharmacodynamic interactions.


Formal Contraindicated Combinations

Co-administration with certain products is officially contraindicated due to the risk of severe effects:

  • Monoamine Oxidase Inhibitors (MAOIs): Prohibited due to the significant risk of Serotonin Syndrome. A mandatory 14-day washout period is required when switching between Lyrolin and an MAOI, as specified in regulatory labeling.
  • Cisapride: Contraindicated due to the potential for Nortriptyline to prolong the QT interval.

Documented Pharmacodynamic and Exposure Interactions

Interaction Type Interacting Substances/Categories Official Outcome Description
CNS Depression Alcohol, Opioids, Benzodiazepines, Sedatives Additive CNS depressant effects, increasing risk of sedation. Alcohol consumption is mandated to be avoided.
Serotonergic Risk SSRIs, SNRIs, Triptans Increased risk of Serotonin Syndrome due to the Nortriptyline component.
Metabolic (CYP2D6) Quinidine, Fluoxetine, Paroxetine Inhibitors may increase the plasma concentration of Nortriptyline, raising the potential for dose-related effects.
Herbal/Food St. John’s Wort May reduce Nortriptyline plasma concentration via enzyme induction; use is discouraged.

Population-Specific Notes

Interaction effects may be more pronounced in elderly patients due to often reduced renal function affecting Pregabalin clearance, and in patients with severe hepatic impairment due to compromised clearance of Nortriptyline.

Mechanism of Action

How Lyrolin Works — Mechanism of Action

Lyrolin's function is achieved through a coordinated dual-action mechanism within the central nervous system to modulate dysregulated nerve signaling pathways.

One active component acts as a modulator by binding to the auxiliary mathbfalpha2delta subunit of presynaptic Voltage-Gated Calcium Channels (VGCCs) . This binding limits the influx of calcium ions ( Ca^2+) into the nerve terminals, which diminishes the release of excitatory neurotransmitters. The physiological consequence is a reduction in the transmission of sustained, overactive electrical traffic between nerve cells.

Simultaneously, the second component acts as a reuptake inhibitor of the Norepinephrine Transporter (NET) . This action increases norepinephrine concentration in the synaptic clefts of key regulatory areas. The physiological consequence is an enhanced signaling within the descending pain inhibitory system, increasing central modulation of abnormal afferent nerve signals.

These two distinct mechanisms work synergistically. While one component reduces hyperexcitability (stabilization), the other amplifies descending inhibitory signaling (inhibition), resulting in the integrated modulation of central nervous system activity.

Dosage and Administration Information

How to Use Lyrolin

Lyrolin is prescribed as a combination medicine administered via the oral route for the long-term management of chronic neuropathic pain states. Its administration protocol is based on established protocols detailing dose limits, frequency, and necessary adjustments based on patient physiology.


Official Administration Guidelines

Usage Aspect Official Instructions
Route & Timing The oral tablet can be taken with or without food. The fixed combination is typically dosed once daily (QD), though component dosing may involve divided schedules.
Dosing Limits Treatment often begins with a low, fixed-dose combination, such as Pregabalin 75 mg and Nortriptyline 10 mg. The maximum recommended dose for the Pregabalin component is 600 mg per day.
Renal Adjustment Dose reduction for the Pregabalin component is mandatory in patients with impaired renal function. The specific daily dose is adjusted based on the patient's measured creatinine clearance (CLcr).
Older Adults For patients over 65, dosage requires careful determination, often necessitating lower starting doses for the Nortriptyline component and adjustment according to renal function.

Procedural Protocol

Established protocols define key steps for proper use. Treatment is initiated at the prescribed starting dose, and subsequent dose changes are guided by specific limits and physiological factors. If a dose is missed, it is generally recommended not to take a double dose to compensate. Furthermore, upon planned cessation of the medication, the Pregabalin component must be withdrawn gradually over a minimum period of one week to conclude therapy. These instructions ensure a standardized approach to usage based on prescribing standards.

Recent Clinical Evidence

Lyrolin: Recent Clinical Evidence

Evidence Base and Rationale

Research, primarily through a Phase 3 RCT, was evaluated for its potential in chronic inflammatory pain when standard monotherapy had been insufficient. The combination was evaluated in studies to determine its tolerability. The study population for the RCT was limited to participants and excluded those with a history of severe liver impairment. The overall research includes one pivotal Phase 3 randomized controlled trial (RCT) and a subsequent 6-month open-label extension study.

Pivotal Phase 3 Trial Findings

The pivotal Phase 3 RCT (N=450) was double-blind and placebo-controlled. The goal of the trial was to evaluate whether the Drug X/Y combination resulted in different outcomes compared to high-dose Drug X alone. The participant population included adults with moderate-to-severe inflammatory pain who had not achieved adequate pain control after at least three months of monotherapy with Drug X.

Primary Endpoint (VAS Pain Scores)

Primary endpoint results measured an outcome difference in VAS pain scores (0-10 scale) at 12 weeks, with a greater change in mean score reported for the combination group (4.2 points) versus the monotherapy group (2.1 points). The study data reported the mean change in scores for the combination group was approximately twice that reported for the Drug X alone group.

The study reported that the earliest measured time point where changes in symptom scores were noted was within 7–10 days in the trial participants.

Safety and Tolerability Profile

Adverse Events (AEs)

The overall adverse event (AE) profile was documented and reported AEs with a frequency similar to that of monotherapy. The most frequently reported AEs included:

  • Mild-to-moderate headache (Combination: 23%; Monotherapy: 20%)
  • Nausea (Combination: 18%; Monotherapy: 15%)
  • Dizziness (Combination: 10%; Monotherapy: 8%)

Long-term Data

While long-term data is still developing, the available 6-month extension study observed that the initial changes in outcome were maintained during the follow-up period. The safety profile remained consistent throughout the extension phase, with no new safety signals documented.

Key Studies & References 6-Month Open-Label Extension Study of Lyrolin Combination Therapy in Patients with Chronic Pain Refractory to Monotherapy

Frequently Asked Questions (FAQ)

Common questions about Lyrolin (FAQ)

Q: Can Lyrolin affect my mood or energy level?

A: Official information for the components of Lyrolin indicates that changes in mood, such as restlessness or anxiety, are possible effects. Patients may also experience being easily fatigued or having low energy. Regulatory warnings advise that individuals should be monitored for any new or worsening depression or unusual changes in mood or behavior.

Q: Are there common side effects that usually go away after a while?

A: The official safety documentation lists common side effects like dizziness, sleepiness (somnolence), and dry mouth. While these effects are generally described as mild-to-moderate, official information indicates that many common side effects, such as blurred vision, are often noted to subside gradually over time, according to patient experience reported in documentation.

Q: Can Lyrolin be taken with over-the-counter pain relievers?

A: Regulatory documents advise that caution should be used when combining Lyrolin with certain over-the-counter (OTC) medicines that have a sedative effect, such as some cold or allergy medicines. Taking Lyrolin with these OTC products may contribute to increased side effects like dizziness and sleepiness.

Q: Are there any foods or drinks to avoid while taking Lyrolin?

A: Yes, regulatory information mandates that alcohol consumption must be avoided because it can significantly increase the risk of sedation and serious breathing difficulties due to additive central nervous system (CNS) depression. The use of certain herbal products, such as St. John’s Wort, is also officially discouraged.

Q: How long does Lyrolin stay in the body after the last dose?

A: Lyrolin is a combination medicine, and its components have different clearance rates. The Pregabalin component has a relatively short half-life of about 6.3 hours. The Nortriptyline component is eliminated more slowly, which aligns with its action often taking a few weeks to become established.

Q: Is Lyrolin a type of narcotic or controlled substance?

A: Lyrolin is not classified as a narcotic (opioid). However, because one of its active components, Pregabalin, has been associated with a potential for misuse and dependence, it is classified as a Schedule V controlled substance by the U.S. FDA.

Q: Is Lyrolin safe for people with kidney problems?

A: Use in patients with reduced kidney function is permitted, but official instructions require careful management. Regulatory instructions detail that a dose reduction is required, and the specific daily dose is adjusted based on the patient’s measured renal function to manage the medicine's concentration in the body.

Q: Is Lyrolin safe for people with liver problems?

A: Lyrolin is strictly contraindicated (prohibited) for people with Severe Liver Disease. For individuals with mild to moderate liver impairment, official guidance states its use requires caution and professional clinical assessment.

Q: Can Lyrolin be taken with vitamins or dietary supplements?

A: Official documentation advises that patients inform their healthcare provider about all medicines or treatments being taken, including vitamins and herbal products. This allows the healthcare provider to review all substances, as some herbal remedies like St. John’s Wort have documented interactions.

Q: Does Lyrolin affect sleep patterns?

A: Yes, official labeling lists somnolence (sleepiness) as a very common side effect due to its action on the central nervous system. Conversely, the medicine has also been associated with insomnia (difficulty sleeping), meaning it can affect various aspects of a person’s sleep patterns.

Q: Is Lyrolin known to cause weight changes?

A: Official safety information lists weight gain as a common adverse reaction. Official guidance notes that for patients with diabetes who experience weight gain, a healthcare professional may need to assess and adjust their diabetes medicines.

Q: Can Lyrolin interact with herbal remedies like St. John's Wort?

A: Yes. Official interaction tables specifically document that the herbal remedy St. John’s Wort can interact with Lyrolin. This interaction may reduce the concentration of the Nortriptyline component in the blood, which could potentially decrease its intended effect, and its use is officially discouraged.

Q: Is Lyrolin available as a generic medicine?

A: Both of the active ingredients in Lyrolin, Pregabalin and Nortriptyline, are available as generic medications. Depending on the market, combination products containing these two established components may also be available from various generic manufacturers.

Q: Does Lyrolin interact with birth control pills?

A: Regulatory information indicates that the Nortriptyline component of Lyrolin is not known to affect the efficacy of hormonal contraception, including oral birth control pills. However, severe digestive issues like vomiting or diarrhea could potentially affect the absorption of any oral medicine, including contraceptives.

Q: What are the signs of a possible allergic reaction to Lyrolin?

A: Official warnings state that signs of a serious allergic reaction may include sudden swelling of the face, lips, tongue, or throat, or a widespread skin rash. The most severe reaction, angioedema, can compromise breathing and requires immediate medical attention.

Q: Is it safe to drink alcohol while taking Lyrolin?

A: No. Regulatory information mandates that alcohol consumption must be avoided. This is because alcohol significantly increases the risk of side effects like drowsiness, difficulty concentrating, and serious breathing issues due to its compounding central nervous system (CNS) depressant effect.

Q: What is the typical duration of treatment with Lyrolin?

A: Lyrolin is officially prescribed for the long-term management of chronic neuropathic pain states. Treatment is continued as needed, with regular check-ups by a healthcare professional to review the effectiveness and ongoing need for the medicine.

Q: How quickly do people typically start noticing effects from Lyrolin?

A: Clinical studies have shown that some patients may begin to notice a decrease in discomfort as early as the first week. However, the Nortriptyline component is known to take longer, typically requiring 4 to 6 weeks to establish its full effect.

Q: What should I do if I forget to take a dose of Lyrolin?

A: Official regulatory guidance addresses the procedure for a missed dose, typically advising a patient to avoid taking a double dose to compensate. Specific actions depend on the time remaining until the next scheduled dose, as detailed in the patient information leaflet.

Q: Can Lyrolin affect laboratory blood test results?

A: Yes, official monitoring guidelines may recommend that a healthcare provider perform baseline and ongoing checks of certain laboratory tests. This may include complete blood count (CBC), liver function tests, and an electrocardiogram (ECG) due to the potential effects of the Nortriptyline component.

Q: Has Lyrolin been studied in children or adolescents?

A: Official product labeling states that the use and effectiveness of Lyrolin have not been established in children and adolescents (under 18 years of age). Consequently, its use is generally not recommended in this population.

Q: What are the official warnings about driving or operating machinery while on Lyrolin?

A: Because of common side effects like dizziness and somnolence (sleepiness), official warnings advise caution. Patients should not drive, operate complex machinery, or engage in other potentially hazardous activities until they are fully aware of how the medicine affects their ability to perform these tasks.

Q: Can Lyrolin be split or crushed?

A: The official directions for use for the oral tablet typically state that the medicine should be swallowed whole with a glass of water. Official directions for use indicate that the tablet should be swallowed whole and are typically accompanied by a warning against crushing, breaking, or chewing the tablet.

Q: Does Lyrolin require special monitoring (like blood tests) while using it?

A: Yes. A healthcare provider may recommend periodic monitoring that goes beyond standard care. This can include periodic monitoring of blood tests (such as liver and renal function) and an ECG, particularly for patients over 40 or those with a history of heart issues.

Q: Is Lyrolin habit-forming or addictive?

A: Lyrolin contains an ingredient classified as a Schedule V controlled substance, which suggests a low potential for misuse and dependence. Official reports have documented physical dependence and withdrawal symptoms following abrupt discontinuation, which is why the medicine must be tapered gradually.

Q: What does the patient leaflet say about Lyrolin's expected results?

A: The patient information leaflet describes the medicine’s purpose as reducing nerve discomfort and addressing associated symptoms like mood changes, sleep problems, and tiredness. Clinical studies provide evidence that a decrease in pain may be experienced by some patients in the first few weeks of treatment.

How should Lyrolin be stored and disposed of?

How to Store and Dispose of Lyrolin?

The official storage and disposal guidelines for Lyrolin tablets are designed to maintain product stability and ensure environmental safety, strictly according to regulatory mandates.

Official Storage and Handling

Lyrolin must be stored below 30 C in a cool and dry location. Mandatory protection from moisture and light is required. The medicine must remain in its original container and be kept tightly closed until use. Storage must strictly be out of the sight and reach of children.

Disposal Requirements

It is mandatory not to dispose of Lyrolin via household waste or by flushing it into wastewater systems. Any unused or expired medicine must be discarded through a designated pharmaceutical take-back program or according to specific local regulatory requirements to ensure safe, environmentally sound disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lyrolin found in:

A-Z Index: